Investigational drug · Phase 3
BI 1015550
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Diseases, Interstitial, Idiopathic Pulmonary Fibrosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
29
Any phase or sponsor naming "BI 1015550"
First trial start
2022
Nov 16, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BI 1015550", any sponsor or status.
- Phase 121
Conditions studied
As listed on its trial records.
- Lung Diseases, Interstitial
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BI 1015550" as an intervention, largest first.
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06238622 · 1,666 participants · Start Sep 26, 2024 · Primary completion Apr 28, 2027
Drug: Nerandomilast · For: Idiopathic Pulmonary Fibrosis; Progressive Pulmonary Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 375 sites in all
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05321082 · 1,178 participants · Start Nov 16, 2022 · Primary completion Dec 18, 2024
Drug: BI 1015550; Placebo · For: Lung Diseases, Interstitial
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 400 sites in all
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT05321069 · 1,177 participants · Start Oct 6, 2022 · Primary completion Aug 16, 2024
Drug: BI 1015550; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 334 sites in all
- Platform Clinical Study for Conquering SclerodermaPivotal-lookingRecruiting
Scleroderma Research Foundation, Inc.Academic, hospital or other
NCT06195072 · 400 participants (planned) · Start Apr 15, 2024 · Primary completion Nov 2026
Drug: Amlitelimab; BI 1015550 (Nerandomilast) and 1 more · For: Interstitial Lung Disease Due to Systemic Disease; Scleroderma
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 34 sites in all
- A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT04419506 · 147 participants · Start Jul 28, 2020 · Primary completion Oct 6, 2021
Drug: BI 1015550; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Clearwater, Florida; Gainesville, Florida; Kansas City, Kansas · 75 sites in all
- A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07201922 · 80 participants (planned) · Start Feb 10, 2026 · Primary completion May 14, 2029
Drug: Nerandomilast; Placebo · For: Familial Pulmonary Fibrosis; Interstitial Lung Abnormalities; Interstitial Lung Diseases
Sites: Los Angeles, California; Aurora, Colorado; Kissimmee, Florida · 55 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT01594515 · 70 participants · Start May 2012 · Primary completion Sep 2012
Drug: BI 1015550; BI 1015550 and 8 more · For: Healthy
Sites: Ingelheim, Germany
Avraham UntermanAcademic, hospital or other
NCT07919015 · 70 participants (planned) · Start Feb 1, 2026 · Primary completion Jun 30, 2027
Drug: Nerandomilast · For: Idiopathic Pulmonary Fibrosis (IPF); Progressive Pulmonary Fibrosis
Sites: Ashkelon, Israel; Haifa, Israel; Ramat Gan, Israel · 4 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT06408870 · 64 participants · Start Jun 6, 2024 · Primary completion Aug 28, 2024
Drug: BI 1015550 · For: Healthy
Sites: Mannheim, Germany
Boehringer IngelheimBoehringer Ingelheim
NCT06393127 · 64 participants · Start Jun 4, 2024 · Primary completion Sep 10, 2024
Drug: Nerandomilast; Nerandomilast · For: Healthy
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Nerandomilast for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Clinical Efficacy, Safety, and Place in Therapy.
Bui PT, St Onge E, Sotolongo-Miranda H, et al. · Ann Pharmacother 2026
- Mechanism, Clinical Evidence, and Therapeutic Role of Nerandomilast in Fibrotic Lung Diseases.
Daas O, Al Sa'ed M, Abuhamdan A, et al. · Clin Drug Investig 2026
- Nerandomilast (BI 1015550) attenuating pulmonary fibrosis in a mouse model of rheumatoid arthritis-associated interstitial lung disease by modulating the TGF-β1/PI3K/Akt signaling pathway.
Wang X, Liu X, Zhong X, et al. · J Thorac Dis 2026
- Precision Modulation of the PDE4 Pathway: The Emerging Role of Nerandomilast in Pulmonary Fibrosis.
Bishop K, Santana JM, Dietrich E, et al. · J Pharm Technol 2026
- Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.
Cui X, Li W, Chai H, et al. · RMD Open 2026
- Integrating Network Pharmacology, Molecular Dynamics, Machine Learning, and Animal Experiments to Decipher the Anti-fibrotic Mechanism of BI 1015550 in Idiopathic Pulmonary Fibrosis.
Jiao L, Zhang C · Curr Comput Aided Drug Des 2026
Also in development for Lung Diseases, Interstitial
- TX000045Phase 22 trials
Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Boehringer Ingelheim.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.